Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone (GH), does not contain GH sequence and ...

Ethyreal Bio has exited stealth with $101 million in funding, joining the queue of companies preparing to challenge Amgen’s Tepezza. Backed by series A and B round investors, including Atlas Venture ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by dysregulation in humoral immunity and sustained activation of B cells and autoantibody release, where BAFF (B-cell ...

Shanghai Scizeng Medical Technology Co., LTD, a subsidiary of Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), RTW Investments, LP ("RTW"), and Yarrow Bioscience, Inc. ("Yarrow") today ...

DelveInsight's “Endometriosis Pipeline Insight 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Endometriosis pipeline landscape. It covers the Endometriosis ...

Shanghai Scizeng Medical Technology Co Ltd - a subsidiary of Changchun GeneScience Pharmaceutical Co Ltd (GenSci), RTW Investments, a New York-based global full life-cycle investment firm and Yarrow ...

BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, and China, that involves near-term payments of $90 million with another ...

Following closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") ...

Shanghai Scizeng Medical Technology, a subsidiary of Changchun GeneScience Pharmaceutical (GenSci), RTW Investments and privately-held US biotech Yarrow Bioscience have announced an exclusive global ...

Yarrow Bioscience, financially backed by founder RTW Investments, will pay $70 million upfront for ex-China rights to a potentially first-in-class TSHR antibody drug. (Pro2sound/iStock/Getty Images ...

Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology disorders GenSci to receive $70 million ...

DelveInsight's 'Thyroid Eye Disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline thyroid eye disease therapies in various stages of clinical development, major ...